Tanaka A, Nishihara S, Misawa T, Ibayashi H
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Jpn J Pharmacol. 1987 Sep;45(1):97-105. doi: 10.1254/jjp.45.97.
3H-Cimetidine binding to plasma membranes of isolated guinea pig gastric glands was investigated, and the effects of five H2-receptor antagonists on 3H-cimetidine binding and histamine stimulation of cellular cAMP were compared. Of the five cations tested, Cu++ markedly increased specific 3H-cimetidine binding. 3H-Cimetidine had high affinity (Kd = 0.41 x 10(-6) M) and low affinity (Kd = 12.8 x 10(-6) M) binding sites. Cimetidine and etintidine were potent inhibitors of 3H-cimetidine binding, while famotidine, ranitidine and TZU-0460 were not. Histamine stimulation of cellular cAMP was competitively inhibited by H2-receptor antagonists yielding pA2 values of 6.41 for cimetidine, 6.82 for etintidine, 6.87 for ranitidine, 6.94 for TZU-0460 and 7.60 for famotidine. Because the KB value (log KB = -pA2) of 0.39 x 10(-6) M for cimetidine is close to the Kd value for the high affinity 3H-cimetidine binding site, it is presumed to represent a part of the H2-receptor, and the relative potency of etintidine against cimetidine in inhibiting 3H-cimetidine binding is similar to that in inhibiting histamine stimulation of cellular cAMP. These results suggest that imidazole-derived H2-receptor antagonists (cimetidine and etintidine) and non-imidazole H2-receptor antagonists (famotidine, ranitidine and TZU-0460) compete with histamine at different sites on the H2-receptor of the gastric glands.
研究了3H-西咪替丁与分离的豚鼠胃腺质膜的结合,并比较了五种H2受体拮抗剂对3H-西咪替丁结合以及组胺刺激细胞cAMP的影响。在所测试的五种阳离子中,Cu++显著增加了特异性3H-西咪替丁结合。3H-西咪替丁具有高亲和力(Kd = 0.41×10(-6) M)和低亲和力(Kd = 12.8×10(-6) M)结合位点。西咪替丁和依替丁是3H-西咪替丁结合的强效抑制剂,而法莫替丁、雷尼替丁和TZU-0460则不是。组胺刺激细胞cAMP受到H2受体拮抗剂的竞争性抑制,西咪替丁的pA2值为6.41,依替丁为6.82,雷尼替丁为6.87,TZU-0460为6.94,法莫替丁为7.60。由于西咪替丁的KB值(log KB = -pA2)为0.39×10(-6) M,接近高亲和力3H-西咪替丁结合位点的Kd值,推测它代表了H2受体的一部分,并且依替丁在抑制3H-西咪替丁结合方面相对于西咪替丁的相对效力与在抑制组胺刺激细胞cAMP方面相似。这些结果表明,咪唑衍生的H2受体拮抗剂(西咪替丁和依替丁)和非咪唑H2受体拮抗剂(法莫替丁、雷尼替丁和TZU-0460)在胃腺H2受体的不同位点与组胺竞争。